Cell-based clinical trials are ongoing. According to previous clinical studies, NK cell and MSC-therapy is a good candidate for the treatment of COVID-19 without preclinical studies. However, the preparation time of suitable cell sources and the cost of these treatments are challenging.

Dear Dr Ali: The following should help:

Article Cell-Based Therapies for COVID-19: Proper Clinical Investiga...

Best regards

Although cell-based therapy could have potential role in targetting a perticular problem in covid-19. But the therapy may not be so good as

development of specific vaccine for pendemic covid-19.

Stem cell therapy is not yet proved it needs time and preclinical trials ... convalescent plasma is more applicable

Seems molecular etiology of COVID-19 has not been identified, even. Development of specific vaccine....Long ways to go. Its gonna take time. Prior to that the we need to overcome this epidemic.

Since COVID-19 aims at attacking pneumocytes, l think cell based therapy might contribute to the treatment of the disease. This will help Target specific cells in lungs where the vaccines or medicine produced will match with specific receptors on the pneumocytes in the lungs for effective pharmacological and immunological effect.

sounds good. How actually to materialize it, is billion dollars query, in current perspective.

Cell-based clinical trials are ongoing. According to previous clinical studies, NK cell and MSC-therapy is a good candidate for the treatment of COVID-19 without preclinical studies. However, the preparation time of suitable cell sources and the cost of these treatments are challenging.

Please refer to the following paper. This might be of help:

Article Combating COVID-19 with Mesenchymal Stem Cell therapy

Rajarshi, K., Chatterjee, A., & Ray, S. (2020). Combating COVID-19 with Mesenchymal Stem Cell therapy. Biotechnology Reports, e00467.

Yes, there is two possible mechanisms including:1) MSCs can be used due to their impressiveness properties, leading to the attenuation of inflammatory responses against corona virus, and 2)stem cell can be used after in vitro differentiation intro alveolar type 2 like cells upon exposure with specific growth factor, replacing damaged lung tissues, hypothetically. I think that cell therapy may be a rational therapeutic strategy in this context.

I believe that cell therapy will be one of the important and successful treatments in the covid 19 patience in the future.

In my opinion, one of the concerns in this field is cost.

Severe cases of COVID‐19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID‐19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo‐capillary barriers.

Article Cell‐based therapy to reduce mortality from COVID ‐19: Syste...

https://cdn.ymaws.com/isctglobal.org/resource/resmgr/telegraft_april_2020/telegraft_27.2_covid-19.pdf

In a meta‐analysis study of clinical MSC therapy for acute respiratory distress syndrome has been reported that all allogeneic-MSCs from bone marrow, umbilical cord, menstrual blood, adipose tissue, and other sources show a favorable outcome but did not reach statistical significance. No related serious adverse events were reported, and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2/FiO2 ratio, alveolo‐capillary injury), and inflammatory biomarker levels. These data suggest that MSCs can be a suitable and promising candidate for the treatment of ongoing COVID-19 clinical trials.

Additional information: https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.20-0146